CURRICULUM VITAE

Wade Yasuo Nishimoto, M.D.

California Medical License

G56797

EDUCATION

Doctor of Medicine - John A. Burns School of Medicine

University of Hawaii, Honolulu, Hawaii

1980 - 1984

B.S. - Microbiology & Immunology

University of Washington, Seattle, Washington

1976 – 1980

EMPLOYMENT EXPERIENCE

Partner - California Hematology Oncology Medical Group
Los Angeles, CA
1990 - Present

Fellowship in Hematology/Oncology

UC Irvine Integrated Fellowship

UC Irvine Med Ctr/Long Beach V.A.M.C.

1987 – 1990

Residency – Internal Medical

UC Irvine Integrated Med Program

Long Beach V.A. Medical Center

Long Beach, CA

1985 – 1987

Internship – Internal Medical

UC Irvine Integrated Med Program

Long Beach V.A. Medical Center

Long Beach, CA

1984 – 1985

CERTIFICATION & LICENSURE

Diplomate, National Board of Medical Examiners, Part I, II, III

Licensed Physician

State of California

1986 to Present

American Board of Internal Medicine
1988

American College of Physicians Medical Oncology Boards

1991

Board Eligible – Hematology

HOSPITAL AFFILIATIONS

Centinela Hospital Medical Center
Torrance Memorial Medical Center
Daniel Freeman Memorial Medical Center
Robert F. Kennedy Medical Center
Little Company of Mary Medical Center
South Bay Hospital

HONORS

Phi Beta Kappa

1980

Cum Laude Graduate

1980

Brodsky Pulmonary Award

1984

Outstanding Resident Award

1987

PROFESSIONAL SOCIETIES

American Society of Clinical Oncology (ASCO)

Southern California Academy of Clinical Oncology (SCACO)

RESEARCH EXPERIENCE

Phase II Trial in Patients with Advanced or Metastatic Non-Small Cell Lung Cancer.
Double-Blind, Placebo-Controlled, prevention of Acute & Delayed Chemotherapy-Induced Emesis.
Double-Blind, Placebo-Controlled, of acute and delayed Chemotherapy-Induced Emesis.
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Examine the Safety, Tolerability, and Efficacy of MK-0869 for the Prevention of Chemo-Induced Nausea and Vomiting Associated with High-Dose Cisplatin.
Phase III Trial in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) Who Were Previously Treated with Chemotherapy.
Phase III Study in Patients with Unresectable, Locally Recurrent or Metastatic Breast Cancer.

ABOUT CHOMG CHOMG EVENTS TO CHOMG

RESOURCE PAGE TO BIOS HOME

BACK TO CHOMG STAFF EMAIL US

ABOUT CHOMG	CHOMG EVENTS	TO CHOMG
RESOURCE PAGE	TO BIOS	HOME
BACK TO CHOMG STAFF	EMAIL US